Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It enhances magnetic resonance imaging of specific organs and vascular structures in adult patients.

GNH USA supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of various anatomical regions.

- Brain and spinal cord MRI: Improves lesion detection and anatomical detail on T1‑weighted images. - Liver MRI: Enhances lesion conspicuity and vascular phase imaging for hepatic assessment. - Cardiovascular MRI: Provides high‑contrast delineation of cardiac chambers, myocardium and great vessels. - Magnetic resonance angiography (MRA): Increases signal intensity of blood vessels for clearer angiographic studies.

Adverse reactions may occur following intravenous administration of Multihance.

Common Side Effects: - Nausea: Mild to moderate feeling of stomach upset. - Headache: Transient pain often resolving without intervention. - Injection site discomfort: Burning or pain at the infusion site. - Warmth sensation: Brief feeling of heat during injection. - Dizziness: Light‑headedness that usually subsides quickly. - Mild rash: Localized skin irritation.

Serious or Rare Side Effects: - Anaphylactic reaction: Severe allergic response requiring immediate medical attention. - Nephrogenic systemic fibrosis (NSF): Fibrotic skin and organ changes in patients with severe renal impairment. - Severe hypotension: Marked drop in blood pressure post‑injection. - Cardiac arrest: Rare but life‑threatening cardiac event. - Pulmonary edema: Accumulation of fluid in the lungs, especially in compromised patients.

Use of Multihance requires careful assessment of patient-specific factors.

- Renal function assessment: Evaluate glomerular filtration rate before administration. - Pregnancy Category C: Use only if potential benefit justifies potential risk to the fetus. - Breastfeeding caution: Consider discontinuing nursing or withholding the drug. - Known gadolinium allergy: Avoid use in patients with documented hypersensitivity. - Monitor for NSF: Particularly in patients with severe renal dysfunction. - Pediatric use: Exercise caution and follow specialist guidance. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Gadobenate dimeglumine may interact with other agents that affect renal function or gadolinium exposure.

Major Interactions (Avoid): - Concurrent administration of other gadolinium‑based contrast agents: Increases cumulative gadolinium load. - Use with nephrotoxic drugs (e.g., high‑dose aminoglycosides, iodinated contrast): Heightens risk of renal impairment.

Moderate Interactions (Monitor Closely): - Loop diuretics: May alter renal clearance, requiring kidney function monitoring. - Beta‑blockers: Can mask hypotensive reactions, necessitating blood pressure observation. - Steroids: May reduce incidence of mild reactions but require monitoring for immunosuppression effects.